119 related articles for article (PubMed ID: 32342528)
21. How agarose gels surrounding PLGA implants limit swelling and slow down drug release.
Bassand C; Verin J; Lamatsch M; Siepmann F; Siepmann J
J Control Release; 2022 Mar; 343():255-266. PubMed ID: 35085697
[TBL] [Abstract][Full Text] [Related]
22. Development of Biodegradable Injectable In situ Forming Implants for Sustained Release of Lornoxicam.
Christian R; Thakkar V; Patel T; Gohel M; Baldaniya L; Shah P; Pandya T; Gandhi T
Curr Drug Deliv; 2019; 16(1):66-78. PubMed ID: 30264681
[TBL] [Abstract][Full Text] [Related]
23. Influence of drying processes on the structures, morphology and
Wu Z; Zhao M; Zhang W; Yang Z; Xu S; Shang Q
J Microencapsul; 2019 Jan; 36(1):21-31. PubMed ID: 30757946
[TBL] [Abstract][Full Text] [Related]
24. Tunable sustained release drug delivery system based on mononuclear aqueous core-polymer shell microcapsules.
Abulateefeh SR; Alkawareek MY; Alkilany AM
Int J Pharm; 2019 Mar; 558():291-298. PubMed ID: 30641178
[TBL] [Abstract][Full Text] [Related]
25. Non-invasive in vivo characterization of microclimate pH inside in situ forming PLGA implants using multispectral fluorescence imaging.
Schädlich A; Kempe S; Mäder K
J Control Release; 2014 Apr; 179():52-62. PubMed ID: 24503251
[TBL] [Abstract][Full Text] [Related]
26. Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.
Schmitt V; Kesch C; Jackson JK; Bidnur S; Beraldi E; Yago V; Bowden M; Gleave ME
Pharm Res; 2020 Jan; 37(3):36. PubMed ID: 31965346
[TBL] [Abstract][Full Text] [Related]
27. Biodegradable PLGA implants containing doxorubicin-loaded chitosan nanoparticles for treatment of breast tumor-bearing mice.
Kefayat A; Vaezifar S
Int J Biol Macromol; 2019 Sep; 136():48-56. PubMed ID: 31195043
[TBL] [Abstract][Full Text] [Related]
28. A 'biorelevant' approach to accelerated in vitro drug release testing of a biodegradable, naltrexone implant.
Iyer SS; Barr WH; Karnes HT
Int J Pharm; 2007 Aug; 340(1-2):119-25. PubMed ID: 17482777
[TBL] [Abstract][Full Text] [Related]
29. In-situ forming PLGA implants for intraocular dexamethasone delivery.
Bode C; Kranz H; Siepmann F; Siepmann J
Int J Pharm; 2018 Sep; 548(1):337-348. PubMed ID: 29981408
[TBL] [Abstract][Full Text] [Related]
30. Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems.
Luan X; Bodmeier R
J Control Release; 2006 Jan; 110(2):266-272. PubMed ID: 16300851
[TBL] [Abstract][Full Text] [Related]
31. Development and in vitro characterization of polymeric nanoparticles containing recombinant adrenomedullin-2 intended for therapeutic angiogenesis.
Quadros HC; Santos LMF; Meira CS; Khouri MI; Mattei B; Soares MBP; de Castro-Borges W; Farias LP; Formiga FR
Int J Pharm; 2020 Feb; 576():118997. PubMed ID: 31893542
[TBL] [Abstract][Full Text] [Related]
32. Terbinafine-loaded branched PLGA-based cationic nanoparticles with modifiable properties.
Martiska J; Snejdrova E; Drastik M; Matysova L; Dittrich M; Loskot J; Jilek P
Pharm Dev Technol; 2019 Dec; 24(10):1308-1316. PubMed ID: 31509046
[TBL] [Abstract][Full Text] [Related]
33. Diclofenac sodium loaded PLGA nanoparticles for inflammatory diseases with high anti-inflammatory properties at low dose: Formulation, characterization and in vivo HET-CAM analysis.
Öztürk AA; Namlı İ; Güleç K; Kıyan HT
Microvasc Res; 2020 Jul; 130():103991. PubMed ID: 32105668
[TBL] [Abstract][Full Text] [Related]
34. PLGA implants for controlled drug release: Impact of the diameter.
Bassand C; Freitag J; Benabed L; Verin J; Siepmann F; Siepmann J
Eur J Pharm Biopharm; 2022 Aug; 177():50-60. PubMed ID: 35659920
[TBL] [Abstract][Full Text] [Related]
35. Often neglected: PLGA/PLA swelling orchestrates drug release: HME implants.
Bode C; Kranz H; Fivez A; Siepmann F; Siepmann J
J Control Release; 2019 Jul; 306():97-107. PubMed ID: 31150749
[TBL] [Abstract][Full Text] [Related]
36. Demineralized bone matrix paste formulated with biomimetic PLGA microcarriers for the vancomycin hydrochloride controlled delivery: Release profile, citotoxicity and efficacy against S. aureus.
Govoni M; Lamparelli EP; Ciardulli MC; Santoro A; Oliviero A; Palazzo I; Reverchon E; Vivarelli L; Maso A; Storni E; Donati ME; Ruspaggiari G; Maffulli N; Fini M; Della Porta G; Dallari D
Int J Pharm; 2020 May; 582():119322. PubMed ID: 32298742
[TBL] [Abstract][Full Text] [Related]
37. Design of Experiments (DoE) Approach to Optimize the Sustained Release Microparticles of Gefitinib.
Soni G; Yadav KS; Gupta MK
Curr Drug Deliv; 2019; 16(4):364-374. PubMed ID: 30588883
[TBL] [Abstract][Full Text] [Related]
38. Towards in vitro - In vivo correlation models for in situ forming drug implants.
Wang X; Roy M; Wang R; Kwok O; Wang Y; Wang Y; Qin B; Burgess DJ
J Control Release; 2024 Jun; 372():648-660. PubMed ID: 38936743
[TBL] [Abstract][Full Text] [Related]
39. Effect of the Subcutaneous Environment on Phase-Sensitive In Situ-Forming Implant Drug Release, Degradation, and Microstructure.
Solorio L; Exner AA
J Pharm Sci; 2015 Dec; 104(12):4322-4328. PubMed ID: 26506522
[TBL] [Abstract][Full Text] [Related]
40. In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence.
Nieto K; Pei P; Wang D; Mallery SR; Schwendeman SP
Int J Pharm; 2018 Mar; 538(1-2):48-56. PubMed ID: 29170116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
